scholarly journals An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery

2012 ◽  
Vol 6 (2) ◽  
pp. 521-529 ◽  
Author(s):  
L. F. Willoughby ◽  
T. Schlosser ◽  
S. A. Manning ◽  
J. P. Parisot ◽  
I. P. Street ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Large Scale ◽  
Cancer Drug ◽  
Chemical Screening ◽  
Cancer Drug Discovery ◽  
Anti Cancer ◽  
Screening Platform

Bioinformatics Approaches for Anti-cancer Drug Discovery

2019 ◽  
Vol 21 (1) ◽  
pp. 3-17 ◽  
Author(s):  
Kening Li ◽  
Yuxin Du ◽  
Lu Li ◽  
Dong-Qing Wei
Keyword(s):  
Drug Discovery ◽  
Cancer Therapy ◽  
Biological Network ◽  
Computational Prediction ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Cancer Drug Discovery ◽  
Anti Cancer

Drug discovery is important in cancer therapy and precision medicines. Traditional approaches of drug discovery are mainly based on in vivo animal experiments and in vitro drug screening, but these methods are usually expensive and laborious. In the last decade, omics data explosion provides an opportunity for computational prediction of anti-cancer drugs, improving the efficiency of drug discovery. High-throughput transcriptome data were widely used in biomarkers’ identification and drug prediction by integrating with drug-response data. Moreover, biological network theory and methodology were also successfully applied to the anti-cancer drug discovery, such as studies based on protein-protein interaction network, drug-target network and disease-gene network. In this review, we summarized and discussed the bioinformatics approaches for predicting anti-cancer drugs and drug combinations based on the multi-omic data, including transcriptomics, toxicogenomics, functional genomics and biological network. We believe that the general overview of available databases and current computational methods will be helpful for the development of novel cancer therapy strategies.

Natural Sesquiterpene Lactones in the Prevention and Treatment of Inflammatory Disorders and cancer: A Systematic Study of this Emerging Therapeutic Approach based on Chemical and Pharmacological Aspect

2020 ◽  
Vol 17 (9) ◽  
pp. 1102-1116
Author(s):  
Sudip Kumar Mandal ◽  
Utsab Debnath ◽  
Amresh Kumar ◽  
Sabu Thomas ◽  
Subhash Chandra Mandal ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Biological Activities ◽  
Sesquiterpene Lactones ◽  
Structural Diversity ◽  
Cancer Drug ◽  
Cancer Drug Discovery ◽  
Anti Cancer ◽  
Drug Discovery Program ◽  
Anti Inflammatory ◽  
Family Based

Background and Introduction: Sesquiterpene lactones are a class of secondary metabolite that contains sesquiterpenoids and lactone ring as pharmacophore moiety. A large group of bioactive secondary metabolites such as phytopharmaceuticals belong to this category. From the Asteraceae family-based medicinal plants, more than 5,000 sesquiterpene lactones have been reported so far. Sesquiterpene lactone-based pharmacophore moieties hold promise for broad-spectrum biological activities against cancer, inflammation, parasitic, bacterial, fungal, viral infection and other functional disorders. Moreover, these moiety based phytocompounds have been highlighted with a new dimension in the natural drug discovery program worldwide after the 2015 Medicine Nobel Prize achieved by the Artemisinin researchers. Objective: These bitter substances often contain an α, β-unsaturated-γ-lactone as a major structural backbone, which in recent studies has been explored to be associated with anti-tumor, cytotoxic, and anti-inflammatory action. Recently, the use of sesquiterpene lactones as phytomedicine has been increased. This study will review the prospect of sesquiterpene lactones against inflammation and cancer. Methods: Hence, we emphasized on the different features of this moiety by incorporating its structural diversity on biological activities to explore structure-activity relationships (SAR) against inflammation and cancer. Results: How the dual mode of action such as anti-inflammatory and anti-cancer has been exhibitedby these phytopharmaceuticals will be forecasted in this study. Furthermore, the correlation of anti-inflammatory and anti-cancer activity executed by the sesquiterpene lactones for fruitful phytotherapy will also be revealed in the present review in the milieu of pharmacophore activity relation and pharmacodynamics study as well. Conclusion: So, these metabolites are paramount in phytopharmacological aspects. The present discussion on the future prospect of this moiety based on the reported literature could be a guide for anti-inflammatory and anti-cancer drug discovery programs for the upcoming researchers.

Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery

2016 ◽  
Vol 16 (10) ◽  
pp. 1339-1352 ◽  
Author(s):  
Alessandra C. Pinheiro ◽  
Thais C. Mendonça Nogueira ◽  
Marcus V.N. de Souza
Keyword(s):  
Drug Discovery ◽  
Cancer Drug ◽  
Cancer Drug Discovery ◽  
Anti Cancer

scholarly journals Frontiers in Anti-cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-angiogenic Add-on Therapy in Glioblastoma

2021 ◽  
Author(s):  
Laura Guarnaccia ◽  
Stefania Elena Navone ◽  
Matteo Maria Masseroli ◽  
Melissa Balsamo ◽  
Manuela Caroli ◽  
...  
Keyword(s):  
Target Therapy ◽  
Cancer Drug ◽  
Cancer Drug Discovery ◽  
Average Survival ◽  
Anti Cancer ◽  
Tumor Neovascularization ◽  
Novel Therapeutic Strategies

Glioblastoma (GBM) is the most common primitive tumor in adult central nervous system (CNS), classified as grade IV according to WHO 2016 classification. GBM shows a poor prognosis with an average survival of approximately 15 months, representing an extreme therapeutic challenge. One of its distinctive and aggressive features is aberrant angiogenesis, which drives tumor neovascularization, representing a promising candidate for molecular target therapy. Although several pre-clinical studies and clinical trials have shown promising results, anti-angiogenic drugs have not led to a significant improvement in overall survival (OS), suggesting the necessity of identifying novel therapeutic strategies. Metformin, an anti-hyperglycemic drug of the Biguanides family, used as first line treatment in Type 2 Diabetes Mellitus (T2DM), demonstrated in vitro and in vivo antitumoral efficacy in many different tumors, including GBM. From this evidence, a process of repurposing of the drug has begun, leading to the demonstration of the inhibition of various oncopromoter mechanisms and, consequently, to the identification of the molecular pathways involved. Here, we review and discuss the potential metformin’s antitumoral effects on GBM, inspecting if it could properly act as an anti-angiogenic compound to be considered as a safely add-on therapy in the treatment and management of GBM patients.

A novel tissue-engineered 3D tumor model for anti-cancer drug discovery

2018 ◽  
Vol 11 (1) ◽  
pp. 015004 ◽  
Author(s):  
Wenfang Li ◽  
Xueyan Hu ◽  
Shuaitao Yang ◽  
Shuping Wang ◽  
Chenghong Zhang ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Tumor Model ◽  
Cancer Drug ◽  
Cancer Drug Discovery ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document